PILOT PROGRAM TO ASSIST CERTAIN MEMBERS OF THE ARMED FORCES AND DEPENDENTS WITH ADDITIONAL SUPPLEMENTAL COVERAGE RELATING TO CANCER HT9402-26-RFI-0255
Defense Health Agency · DEFENSE HEALTH AGENCY
Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.
Where this opportunity stands
Every notice posted under solicitation HT9402-26-RFI-0255 in this department, oldest first.
- Sep 4, 2026 · this noticeSpecial Notice
Next steps for this stage
Standard steps for the notice type; not advice about this buyer.
- Answer the notice: this is when the requirement can still be shaped.
- Contact the contracting officer named on the notice.
- Check who won similar work; they are the likely bidders.
What the notice says
The Defense Health Agency (DHA) is currently in the planning phase for partnering with carriers of supplemental insurance focused on cancer coverage. This Request for Information (RFI) is intended to initiate market research efforts as the Government considers structuring processes to meet Congress� intent. Section 734 of the National Defense Authorization Act (NDAA) for Fiscal Year (FY) 2026 (Enclosure 1) requires DHA to establish a pilot program not later than September 30, 2027, under which members of the regular component of the Army, Navy, Marine Corps, Air Force, or Space Force and their… (show all)
dependents enrolled in TRICARE may obtain supplemental cancer insurance for noncovered expenses under a fixed indemnity supplemental benefit. The supplemental coverage is intended to provide financial assistance for noncovered expenses related to cancer screening, diagnosis and treatment that are not otherwise covered by the health care benefits the individuals receive under chapter 55 of title 10, United States Code, or any other benefit provided by the Secretary of Defense. https://www.congress.gov/119/plaws/publ60/PLAW-119publ60.pdf RFI Instructions: Prepare and submit a written response addressing each of the questions below. This response shall not exceed 20 pages in length and should not be solely your company�s general capability statement but instead specifically address the Government�s topics listed in this RFI. Please send your responses to the Defense Health Agency, Managed Care Contracting Division james.goddard22.ctr@health.mil by Close of Business 18 September 2026. RFI Questions: Plan Types and Coverage Scope Describe how a TRICARE specific plan would differ from current commercially available plans. What non-covered services under TRICARE would be covered? Would there be portability options if a beneficiary is no longer eligible for TRICARE? How could your company intend to add value to TRICARE beneficiaries? Describe an applicable case scenario. Coverage Details and Exclusions Detail general coverages provided in similar plans. Would there be any key coverage exclusions and limitations, including but not limited to: Acts of War, specific cancer types, pregnancy, and state-based restrictions? What annual or lifetime maximums on benefits would apply, and what conditions or treatments would be subject to caps or exceptions? What coverage would be provided for non-FDA approved drugs, participation in clinical trials, or other emerging and unproven treatments? Would pre-existing conditions be covered? If yes, what conditions would be included? Would there be any coverage limitations for a recurring diagnosis (remission or new)? In which states does your company offer coverage, and are there any state specific exceptions or restrictions that would apply to a TRICARE specific plan? How would this impact our mobile beneficiary population? Do your company�s plans provide coverage for beneficiaries residing or receiving care overseas? Eligibility and Enrollment Per the NDAA, the Government will not be subsidizing this pilot. To be financially viable, is there a minimum required enrollment threshold for such an unsubsidized, �no cost,� 100% beneficiary paid, group plan to be offered by your company? Is there a preferred eligibility verification process? What would prevent a member from being eligible? Describe the enrollment process and the expected burden on the beneficiary. When would coverage be effective? Any limitations? How would beneficiaries make premium payments? How are premiums structured today (in similar policies)? How would your company structure TRICARE premiums based on pilot requirements? Would premium rates be locked in for the duration of the pilot? Describe the termination of coverage process and the expected burden on the beneficiary. Claims and Payments How are claim payments determined and processed, including if lump sum payments are one-time or recurring, and any applicable limitations? Would payments be taxable as income? How would beneficiaries submit claims/receive payments, and what is the expected burden on the beneficiary? Would there be any third-party liability? If so, please explain. Describe the claims submissions and processing experience, including the average processing time and the availability of digital tools (such as online portals or mobile apps) for beneficiaries to submit and track claims. Reporting and Oversight What beneficiary data would your company provide to the Government/employer (e.g. cost, number of enrollees, denials, customer satisfaction, use case data)? Are there any limitations to data your company would be willing to share? Does your company recommend any specific data metrics DHA should track to accurately report the program�s success, beneficiary satisfaction, and programmatic feasibility to Congress? What board or organization oversees the supplemental insurance industry? Give some examples of standards, grievances, or reporting at a state or federal level. Qualifications How many years of experience does your company have providing supplemental insurance plans? What is your company�s claims acceptance/denial rate? What are the top 10 reasons for denials? How will your company protect beneficiaries� personally identifiable information? Acquisition Strategy What are ways to participate via �no-cost� or similar means? Does your company anticipate any barriers to participating in the pilot based on �no-cost� contract terms? The Government may publish future RFIs or hold an industry day. Communication for both will be made under the same announcement as the RFI. The Government appreciates the time and expense related to this posting. Disclaimer: This announcement does not constitute a commitment, implied or otherwise, to ensure that a solicitation or contract will be issued. Issuance of the RFI is for planning purposes only and does not commit the Government to any contractual agreements or arrangements. The Government is not soliciting proposals with this request. Responses to this announcement will not be returned. The Government is not liable to pay any costs associated with companies responding to this announcement. Issuance of the RFI is intended to provide interested parties with information and provide an opportunity for industry feedback into the preliminary programmatic design. All information received resulting from this RFI will be used by the DHA for market research purposes and programmatic design. However, responses may be releasable to the public under the Freedom of Information Act (FOIA) unless appropriately marked. The DHA, at its discretion, may request respondents to elaborate on information in their written response in writing or through other means. Respondents will not be notified of any results derived from a review of the information provided. Any responses from the Government are subject to change, interested parties will have opportunity to seek clarification from the Government for any remaining questions. CONFIDENTIALITY: No proprietary, classified, confidential, or sensitive information should be included in your response. Industry responses will be shared with DHA staff for the purpose of market research. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s). Potential offerors are instructed to use the question matrix provided in the attachments section for any additional comments or questions for the Government. Responses will be provided at a later date. PRIMARY DHA POINT OF CONTACT: email: marcus.r.webb.civ@health.mil
Who won similar work
392 award notices on SAM.gov in the last 24 months. Matched by: Same agency (Defense Health Agency), any industry: a loose match.
Loose match: same agency, any industry. Read the titles before treating these as competitors.
Single-winner award sizes (392): middle half $75K to $1.3M, median $265K; range $13K to $1.6B.
| Winner | Awards | Value | Last |
|---|---|---|---|
| REES SCIENTIFIC CORPORATION | 5 | $1.9M | Sep 18, 2026 |
| BCG FEDERAL CORP. | 3 | $138.5M | May 27, 2026 |
| A-DEC INC | 3 | $4.9M | Oct 14, 2026 |
| AGILENT TECHNOLOGIES INC · $A · $6.8B | 3 | $2.4M | Oct 6, 2026 |
| O R ELDER INC | 3 | $2.0M | Aug 11, 2026 |
| WERFEN USA LLC | 3 | $666K | Aug 19, 2026 |
| STERIS CORPORATION · $STE · $5.1B | 3 | $351K | Sep 10, 2026 |
| G4S SECURITY SYSTEMS GUAM INC | 3 | $322K | Jul 22, 2026 |
| OptumServe Health Services, Inc. | 2 | $2.7B | Apr 16, 2026 |
| CareSource Military & Veterans Co. Dayton OH 45402 USA | 2 | $110.2M | Nov 21, 2024 |
Value counts single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling; that ceiling is not one company's win, so it is not added in. Revenue next to a ticker is the company's last annual revenue from its 10-K.
- $A reported $6.8B revenue in FY2025. The median single-winner award in these 392 past awards, $265K, is under 0.1% of that. 10-K
- $STE reported $5.1B revenue in FY2026. The median single-winner award in these 392 past awards, $265K, is under 0.1% of that. 10-K
One award's total value against one year of revenue; many awards are paid over several years.
- Oct 14, 2026A-DEC INC$1.2MDental Equipment Delivery, De-installation and Installation Service
- Oct 8, 2026Novartis Pharmaceuticals Corporation$480KSUPPLY of LUTATHERA� (lutetium Lu 177 dotatate) and PLUVICTO� (lutetium Lu 177 vipivotide tetraxetan)
- Oct 7, 2026RAL Investment Corporation$513KNMCSD Modular Furniture and Installation
- Oct 6, 2026AGILENT TECHNOLOGIES INC$350KIHC Reagents and Supplies
- Oct 1, 2026CARDINAL HEALTH 414, LLC$2.4MFDA-Approved Radiopharmaceutical Supplies and Cold Kits
- Oct 1, 2026BLOODWORKS Seattle WA 98104 USA$4.0MBlood Donor Testing Services
- Oct 1, 2026SYSMEX AMERICA, INC$2.7MFY26 Lab Consolidation for Coagulation CPRR Effort
- Sep 30, 2026LINDE GAS & EQUIPMENT INC.$94KInstallation of Bulk Liquid Oxygen Tank
- Sep 29, 2026BIOMERIEUX INC$627KMicrobiology Analyzer and Reagents - Cost per Test
- Sep 29, 2026ASP KOREA LLC$83KSterrad 100NX Plasma Sterilizer Maintenance Services at the 51st Medical Group, at Osan Air Base
Competitive landscape
For the 8 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.
- 0 of these past winners lobbied Defense, Dept of (DOD) or Office of the Secretary of Defense or Joint Chiefs of Staff since 2024 (0 filings)
- 0 of their lobbyists list a past Defense, Dept of (DOD) or Office of the Secretary of Defense or Joint Chiefs of Staff job
- $20K from their corporate PACs since 2024 to members of House Committee on Appropriations, House Committee on Armed Services, Senate Committee on Appropriations, Senate Committee on Armed Services
- 0 foreign-agent (FARA) registrations
Policy around it
Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.
- 0 bills named on the past winners' lobbying filings
- 32 rules from the department in the last 12 months
- 0 executive orders naming the agency in the last 12 months
Market
For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.
- 2 of the past winners are listed companies
- 0 insider buys and 2 insider sells at them in the last 90 days
Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.
Companies are matched to tickers by exact name only. A company we could not match shows no market rows; that is a miss, not a finding.